Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGUI51)

Drug Name

MSDC-0602 Drug Info

Synonyms

MSDC-0602; 1133819-87-0; MSDC 0602; 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione; 2,4-Thiazolidinedione, 5-[[4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-; YAUMOGALQJYOJQ-UHFFFAOYSA-N; SCHEMBL623654; AKOS027382993

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 2	[1]

Cross-matching ID

PubChem CID: 25230266
CAS Number: CAS 1133819-87-0
TTD Drug ID: DMGUI51

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Insulin receptor (INSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meglitinides	DM1OFHN	Type-2 diabetes	5A11	Approved	[3]
Human neutral insulin	DMA5OBU	Diabetic complication	5A2Y	Approved	[4]
Insulin Lyspro recombinant	DM5XHVR	Diabetic complication	5A2Y	Approved	[4]
Insulin, porcine	DMO95XI	Diabetic complication	5A2Y	Approved	[5]
Insulin recombinant	DMYVP5G	Diabetic complication	5A2Y	Approved	[4]
Metformin arginine-hemisuccinimide	DMTPAM3	Type-2 diabetes	5A11	Approved	[6]
Insulin-lispro	DM4O90W	Diabetic complication	5A2Y	Approved	[7]
Insulin-glulisine	DMQI0FU	Diabetic complication	5A2Y	Approved	[8]
Ryzodeq	DMOFP18	Type-2 diabetes	5A11	Approved	[9]
NN5401	DM0QV27	Diabetic complication	5A2Y	Phase 3	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin receptor (INSR)	TTCBFJO	INSR_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01280695) A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients. U.S. National Institutes of Health.
2	Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48.
3	New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
4	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
5	Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.
6	Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91.
7	Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
8	Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).